IJCM  Vol.3 No.3 , May 2012
A Patient with Intravenous Immunoglobulin-Responsive Lower Motor Neuron Syndrome
ABSTRACT
We report a 50-year-old woman who developed localized proximal muscle weakness, in addition to transient elevation of antibodies to GM-1 ganglioside, without multifocal conduction block. She was treated with intravenous immunoglobulin (IVIg) and steroid pulse therapy, which were effective for over 10 years. Her clinical course and laboratory tests were consistent with lower motor neuron syndrome (LMNS) with localized proximal muscle weakness. We suggest that some patients diagnosed as LMNS may remain responsive to IVIg or steroid pulse therapy for a long time.

Cite this paper
T. Kessoku, T. Koide, K. Akiyama, S. Irie, T. Ishihara and F. Yoshii, "A Patient with Intravenous Immunoglobulin-Responsive Lower Motor Neuron Syndrome," International Journal of Clinical Medicine, Vol. 3 No. 3, 2012, pp. 190-193. doi: 10.4236/ijcm.2012.33038.
References
[1]   R. M. Van Den Berg-Vos, L. H. Van Den Berg, J. Visser, M. de Visser, H. Franssen and J. H. Wokke, “The Spectrum of Lower Motor Neuron Syndromes,” Journal of Neurology, Vol. 250, No. 11, 2003, pp. 1279-1292. doi:10.1007/s00415-003-0235-9

[2]   R. M. van den Berg-Vos, J. Visser, H. Franssen, M. de Visser, J. M. B. V. de Jong, S. Kalmijn, J. H. J. Wokke and L. H. van den Berg, “Sporadic Lower Motor Neuron Disease with Adult Onset: Classification of Subtypes,” Brain, Vol. 126, No. 5, 2003, pp. 1036-1047. doi:10.1093/brain/awg117

[3]   J. C. Meadows, C. D. Marsden and D. G. F. Harriman, “Chronic Spinal Muscular Atrophy in Adults: Part 2. Other Forms,” Journal of Neurological Science, Vol. 9, No. 3, 1969, pp. 551-566. doi:10.1016/0022-510X(69)90094-X

[4]   A. E. Harding, P. G. Bradbury and N. M. Murray, “Chronic Asymmetrical Spinal Muscular Atrophy,” Journal of Neurological Science, Vol. 59, No. 1, 1983, pp. 69-83. doi:10.1016/0022-510X(83)90082-5

[5]   A. Pestronk, V. Chaudhry, E. L. Feldman, J. W. Griffin, D. R. Cornblath, E. H. Denys, M. Glasberg, R. W. Kuncl, R. K. Olney and W. C. Yee, “Lower Motor Neuron Syndromes Defined by Patterns of Weakness, Nerve Conduction Abnormalities, and High Titers of Antiglycolipid Antibodies,” Annals of Neurology, Vol. 27, No. 3, 1990, pp. 316-326. doi:10.1002/ana.410270314

[6]   A. Pestronk, D. R. Cornblath, A. A. Ilyas, H. Baba, R. H. Quarles, J. W. Griffin, K. Alderson and R. N. Adams, “A Treatable Multifocal Motor Neuropathy with Antibodies to GM1 Ganglioside,” Annals of Neurology, Vol. 24, No. 1, 1988, pp. 73-78. doi:10.1002/ana.410240113

[7]   V. Chaudhry, A. M. Corse, D. R. Cornblath, R. W. Kuncl, M. L. Freimer and J. W. Griffin, “Multifocal Motor Neuropathy: Electrodiagnostic Features,” Muscle Nerve, Vol. 17, No. 2, 1994, pp. 198-205. doi:10.1002/mus.880170211

[8]   A. Pestronk, G. Lopate, A. J. Kornberg, J. L. Elliott, G. Blume, W. C. Yee and L. T. Goodnough, “Distal Lower Motor Neuron Syndrome with High-Titer Serum IgM Anti-GM1 Antibodies: Improvement Following Immunotherapy with Monthly Plasma Exchange and Intravenous Cyclophosphamide,” Neurology, Vol. 44, No. 11, 1994, pp. 2027-2031.

[9]   C. M. Ellis, S. Leary, J. Payan, C. Shaw, M. Hu, M. O’Brien and P. N. Leigh, “Use of Human Intravenous Immunoglobulin in Lower Motor Neuron Syndromes,” Journal of Neurolgy, Neurosurgery and Psychiatry, Vol. 67, No. 1, 1999, pp. 15-19. doi:10.1136/jnnp.67.1.15

[10]   A. S. Pakiam and G. J. Parry, “Multifocal Motor Neuropathy without Overt Conduction Block,” Muscle Nerve, Vol. 21, No. 2, 1998, pp. 243-245. doi:10.1002/(SICI)1097-4598(199802)21:2<243::AID-MUS14>3.0.CO;2-2

[11]   K. C. Gorson, A. H. Ropper, L. S. Adelman, E. M. raynor and C. B. Saper, “Chronic Motor Axonal Neuropathy: Pathological Evidence of inflammatory Polyradiculoneuropathy,” Muscle Nerve, Vol. 22, No. 2, 1999, pp. 266-270. doi:10.1002/(SICI)1097-4598(199902)22:2<266::AID-MUS17>3.0.CO;2-V

[12]   R. Kaji, S. Kusunoki, K. Mizutani, N. Oka, Y. Kojima, N. Kohara and J. Kimura, “Chronic Motor Axonal Neuropathy Associated with Antibodies Monospecific for N-acetylgalactosaminyl GD1a,” Muscle Nerve, Vol. 23, No. 5, 2000, pp. 702-706. doi:10.1002/(SICI)1097-4598(200005)23:5<702::AID-MUS6>3.0.CO;2-A

[13]   J. S. Katz, R. J. Barohn, S. Kojan, G. I. Wolfe, S. P. Nations, D. S. Saperstein and A. A. Amato, “Axonal Multifocal Motor Neuropathy without Conduction Block or Other Features of Demyelination,” Neurology, Vol. 58, No. 4, 2002, pp. 615-620.

[14]   J. R. Burrell, C. Yiannikas, D. Rowe and M. C. Kiernan, “Predicting a Positive Response to intravenous Immunoglobulin in Isolated Lower Motor Neuron Syndromes,” PLoS One, Vol. 6, No. 10, 2011, p. e27041. doi:10.1371/journal.pone.0027041

[15]   N. Strigl-Pill, A. K?nig, M. Schr?der, H. Beranek, B. G. H. Schoser, M. Spaeth, D. Pongratz and W. Müller-Felber, “Prediction of Response to IVIg Treatment in Patients with Lower Motor Neurone Disorders,” European Journal of Neurology, Vol. 13, No. 2, 2006, pp. 135-140. doi:10.1111/j.1468-1331.2006.01142.x

 
 
Top